Ophthal Medical News about adalimumab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis
Rheumatology International, 11/02/09

Takase K et al. – Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behcet’s disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. The experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.

<< Previous
A reappraisal of the significance of largest basal diameter of...

Next >>
Serum cortisol and testosterone levels in idiopathic central...

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Gastroenterology, 10/28/09 Relevance Score: 89%

The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients
Rheumatology International, 10/28/09 Relevance Score: 88%

Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions
Annals of Rheumatic Diseases, 10/26/09 Relevance Score: 85%

The short-term and long-term efficacy of adalimumab following discontinuation of infliximab
Alimentary Pharmacology and Therapeutics, 10/21/09 Relevance Score: 84%

Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Cochrane Reviews, 10/12/09 Relevance Score: 84%